trial

D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia

NCTId NCT00237809
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 104 (actual)
Sponsored by Yale University
Primary completion 2010-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
104 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2002-09
Primary completion
2010-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
D-serineCognitive Retraining (CRT)

Sponsors

Yale UniversityLead Sponsor
National Alliance for Research on Schizophrenia and DepressionCollaborator
Donaghue Medical Research FoundationCollaborator

Investigators

1
Deepak C D'Souza, M.D.Principal Investigator

Sites

2 total
New Haven, United StatesWest Haven, United States

Linked catalysts

1
D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia — primary completion2010-12

Facts & assertions

4 sourced
Enrollment
104
Phase
PHASE3
Primary Completion Date
2010-12
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
Cognitive Retraining (CRT)
drug
lead_sponsor
Yale University
company
collaborator
National Alliance for Research on Schizophrenia and Depression
company
Donaghue Medical Research Foundation
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Deepak C D'Souza, M.D.
person